Seems like you cannot go to a CE meeting or read a journal without some mention of corneal crosslinking (CXL) lately.  While this procedure has been available in Europe for quite a while, it's just starting to take off in the USA with FDA studies.

According to Avedro's company statement, it is a "privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking".  There must be a lot of fun celebrations at Avedro lately given all their recent advancements:

September 2011 - Avedro received FDA orphan drug status for CXL for the treatment of KCN.

December 2011 - Avedro received a second FDA orphan drug status for CXL for the treatment of post-refractive surgery ectasia.

Early January 2012 - Avedro gets European approval for it's post-LASIK CXL treatment called LASIK Xtra.

Late January 2012 - Avedro recently got Canadian approval for the LASIK Xtra procedure.  Pretty cool, eh?  - jw